Skip to main content
Premium Trial:

Request an Annual Quote

PBL Licenses Quansys Multiplex Arrays

NEW YORK (GenomeWeb News) – PBL InterferonSource has licensed international and limited US rights to sells Quansys Biosciences' Q-Plex multiplex array kits and related products, under an agreement announced by the firms today.

PBL will offer the kits in combination with its own interferon reagents, enabling researchers to examine the relationship of multiple interferons and cytokines simultaneously. The combination will allow researchers to assess cytokine profiles at various points throughout the course of disease, correlate alterations in cytokine profiles with patient responses to therapies, and determine off-target effects of drugs, the firms said.

"This unique blend of cost-effective technology and interferon content should prove extremely beneficial to scientists developing the next generation of autoimmunity, viral, and cancer therapeutics," Robert Pestka, president and CEO of PBL InterferonSource, said in a statement.

Financial and other terms of the license were not disclosed.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.